|
|
Article: Ipsen and Spirogen Redesign Their Collaboration for the Development of SJG-136 (Now SG2000).
- Article from:
- Business Wire
- Article date:
- October 8, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PARIS & LONDON -- Regulatory News:
Ipsen (Euronext : FR0010259150; IPN) and Spirogen Ltd. announced today that the parties have entered into a new agreement superseding their 2003 contractual relationship regarding the DNA minor groove binder SJG-136 (now known as SG2000). The new agreement between the parties will allow Spirogen to continue and lead the clinical development of this first-in-class anticancer agent. SJG-136 is planned to shortly continue clinical development in upcoming National Cancer Institute-sponsored multi-centered Phase II clinical trials in ovarian cancer and haematological malignancies.
Under the new agreement Spirogen is granted ...